Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. [electronic resource]
Producer: 20070330Description: 477-87 p. digitalISSN:- 1473-4877
- Age Factors
- Aged
- Angiogenesis Inhibitors -- therapeutic use
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide -- therapeutic use
- Choroidal Neovascularization -- diagnosis
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Haplorhini
- Humans
- Macular Degeneration -- drug therapy
- Male
- Middle Aged
- Photochemotherapy -- methods
- Porphyrins -- therapeutic use
- Prognosis
- Ranibizumab
- Risk Assessment
- Treatment Outcome
- Verteporfin
- Visual Acuity
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.